CoChat

Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: A randomized, double-blind, placebo-controlled study

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

CONTEXT: Low testosterone (T) levels are often found in obese men with impaired glucose tolerance (IGT) and overt type 2 diabetes (T2DM); however, the mechanisms underlying this condition and its correct therapy are still under debate. OBJECTIVE: To evaluate the effectiveness of clomiphene citrate (CC) in increasing endogenous T levels in obese men with low serum T and with IGT or T2DM treated with metformin (MET). DESIGN: Cross-over, randomized, double-blind, placebo-controlled study. METHODS: 24 obese men, aged 47.3 ±. 6.3 (range 35-55 years), with low T level (≤3 ng/mL) and naïve diagnosis of IGT or T2DM were included. Subjects were randomized to CC 25 mg/day or placebo (Plac) with MET 2 g/day for 3 months. After a 6-week wash-out period, subjects were moved to the alternative arm for additional 3 months. Clinical evaluation and blood exams performed prior to and at the end of treatment. RESULTS: Of 24 randomized, 21 were evaluable, classified as IGT (n = 11) or T2DM (n = 10). Compared to baseline levels, T levels increased significantly after 3 months of CC treatment (3.03±0.80 to 5.99±1.67 ng/mL P<0.001) but not after the Plac treatment (2.87±0.78 to 3.09±0.84 ng/mL P<0.001 between the treatments). T changes were similar in IGT and T2DM subjects. Gonadotropins as well raised significantly after CC treatment (LH 3.83±1.45 to 8.53±6.40 mU/mL; FSH 4.84±1.67 to 10.15±5.08 mU/mL P<0.001 respectively), whereas no changes for LH (3.51±1.59 to 3.63±1.39 mU/mL) but a smooth increased for FSH (4.61±2.49 to 5.39±2.65 mU/mL; P = 0.004) were shown after Plac treatment (LH P = 0.001 and FSH P = 0.002 between treatments). Furthermore, fasting glucose (106.8±23.2 to 101.1±25.7 mg/dL; P = 0.004), insulin (19.3±12.1 to 15.6±10.1 μU/mL; P = 0.010) and HOMA-IR (4.94±2.89 to 3.69±2.12; P = 0.001) decreased significantly during the CC treatment period, whereas no significant changes were observed in any of these parameters in the Plac treatment. CONCLUSIONS: A low dose of CC therapy was able to significantly increase serum T levels in all participants with mild modifications of clinical and metabolic parameters. TRIAL REGISTRATION: EudraCT 2011-000439-10.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0183369

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Study flowchart. Flowchart describing the number of subjects assessed for eligibility, included in the randomization and completed the study.
Fig 1 Study flowchart. Flowchart describing the number of subjects assessed for eligibility, included in the randomization and completed the study.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. S Dhindsa, 2010, Testosterone concentrations in diabetic and nondiabetic obese men, Diabetes Care, 33, 1186, 10.2337/dc09-1649 · DOI · Paper page

Cited by

See all 45

Metadata

Authors
Pelusi, C., Giagulli, V. A., Baccini, M., Fanelli, F., Mezzullo, M., Fazzini, A., Bianchi, N., Carbone, M. D., De Pergola, G., Mastroroberto, M., Morselli Labate, A. M., & Pasquali, R.
Affiliations
  • IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
  • University of Foggia (IT)
Corresponding author
Pasquali, Renato
Venue
PLOS ONE
Published
2017-09-08
Volume
12
Issue
9
Pages
e0183369
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2751936319
Cited by
45
References
48
Citations by year
2026: 5 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 7 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 8
FWCI
4.76
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by-nc-nd)
Funders
Università di Bologna
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
clomiphene citrate, androgen deficiency, hypogonadism, obesity, metformin, impaired glucose tolerance, type 2 diabetes, dysmetabolic syndrome, gonadotropins, luteinizing hormone, follicle-stimulating hormone, testosterone levels, men's health, insulin resistance, hyperandrogenism, hypertriglyceridemia
MeSH terms
Adult, Body Weights and Measures, Clomiphene, Energy Metabolism, Hormones, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Obesity, Testosterone, Biomarkers, Treatment Outcome, Selective Estrogen Receptor Modulators

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: A randomized, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1371/journal.pone.0183369
The paper
Pelusi, C., Giagulli, V. A., Baccini, M., Fanelli, F., Mezzullo, M., Fazzini, A., Bianchi, N., Carbone, M. D., De Pergola, G., Mastroroberto, M., Morselli Labate, A. M., & Pasquali, R. (2017). Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: A randomized, double-blind, placebo-controlled study. PLOS ONE. https://doi.org/10.1371/journal.pone.0183369

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.